Heron Therapeutics
HRTX
176 hedge funds and large institutions have $1.74B invested in Heron Therapeutics in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 77 increasing their positions, 50 reducing their positions, and 43 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 50
6% more call options, than puts
Call options by funds: $7.2M | Put options by funds: $6.8M
0.03% less ownership
Funds ownership: 118.58% → 118.54% (-0.03%)
11% less funds holding
Funds holding: 198 → 176 (-22)
23% less capital invested
Capital invested by funds: $2.27B → $1.74B (-$521M)
44% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 43
73% less funds holding in top 10
Funds holding in top 10: 11 → 3 (-8)
Top Buyers
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$24.7M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$20M |
| 3 |
State Street
Boston,
Massachusetts
|
+$16.6M |
| 4 |
BM
Bridger Management
New York
|
+$16.2M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$14.9M |
Top Sellers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$36.7M |
| 2 |
O
OrbiMed
New York
|
-$26.1M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$19M |
| 4 |
SIM
Stelliam Investment Management
New York
|
-$15.6M |
| 5 |
KAM
Kavi Asset Management
New York
|
-$14.9M |
HRTX Hedge Fund Activity: Q2 2019 in Review
176 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2019, worth a combined $1.74B — down 23% from $2.27B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of HRTX and 24 opened new positions — a net loss of 19 holders — while 50 trimmed existing stakes and 77 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $24.7M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $36.7M sold.
- 176 institutional investors held Heron Therapeutics (HRTX) as of Q2 2019, down from 198 in Q1 2019.
- Funds reported $1.74B of Heron Therapeutics stock for Q2 2019, down 23% quarter-over-quarter.
- 24 funds opened new Heron Therapeutics positions in Q2 2019 and 43 closed out, a net change of -19 holders.
- The largest Heron Therapeutics buyer in Q2 2019 was ArrowMark Colorado Holdings, an estimated $24.7M added.
- The largest Heron Therapeutics seller in Q2 2019 was Rubric Capital Management (New York), an estimated $36.7M sold.
Based on aggregated 13F filings for Q2 2019.